Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1987 May;55(5):1243–1251. doi: 10.1128/iai.55.5.1243-1251.1987

Effect of differences in antibody and complement requirements on phagocytic uptake and intracellular killing of "c" protein-positive and -negative strains of type II group B streptococci.

N R Payne, Y K Kim, P Ferrieri
PMCID: PMC260497  PMID: 3552996

Abstract

The influence of antibody and complement on the polymorphonuclear leukocytic uptake and killing of type II group B streptococci (GBS) was examined with 11 adult sera and three type II strains possessing the trypsin-resistant and trypsin-sensitive components (II/TR+TS) of the "c" (formerly Ibc) protein or two type II strains lacking both components (II/no c) of the c protein. All tested sera mediated a greater than 1 log10 reduction in colony-forming units (CFUR) of a type II/no c strain, even in the absence of measurable type-specific antibody (less than 1.08 micrograms/ml), but only 5 of 11 mediated a greater than 1 log10 CFUR of any type II/TR/TS strain, even in the presence of moderate levels of type-specific antibody. The classical pathway of complement activation appeared to be more important than the alternative pathway, and even absorbed or immunoglobulin G (IgG)-depleted serum (IgG, 10 mg/dl) mediated a greater than 1 log10 CFUR without magnesium ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (magnesium EGTA) chelation. Chelation with magnesium EGTA reduced the CFUR in 4 of 11 test sera and greatly reduced the CFUR in absorbed or IgG-depleted sera for type II/no c strains. Despite variation in the phagocytic killing of two representative strains of type II GBS, both strains were well phagocytized, as measured by radiolabeled bacterial uptake or electron microscopy. This study suggested that poorly killed type II/TR+TS GBS were easily phagocytized but apparently resisted intracellular killing.

Full text

PDF
1251

Images in this article

1248Image
on p.1248
1249Image
on p.1249

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. J., Edwards M. S., Webb B. J., Kasper D. L. Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. J Clin Invest. 1982 Feb;69(2):394–404. doi: 10.1172/JCI110463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker C. J., Webb B. J., Kasper D. L., Edwards M. S. The role of complement and antibody in opsonophagocytosis of type II group B streptococci. J Infect Dis. 1986 Jul;154(1):47–54. doi: 10.1093/infdis/154.1.47. [DOI] [PubMed] [Google Scholar]
  3. Cleat P. H., Coid C. R. Phagocytic and bactericidal activity of human neutrophils against two isolates of Group B streptococci Type Ic of differing pathogenicity. Br J Exp Pathol. 1981 Aug;62(4):393–397. [PMC free article] [PubMed] [Google Scholar]
  4. Edwards M. S., Baker C. J., Kasper D. L. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis. 1979 Dec;140(6):1004–1008. doi: 10.1093/infdis/140.6.1004. [DOI] [PubMed] [Google Scholar]
  5. Falk R. J., Dalmasso A. P., Kim Y., Tsai C. H., Scheinman J. I., Gewurz H., Michael A. F. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest. 1983 Aug;72(2):560–573. doi: 10.1172/JCI111004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ferrieri P., Burke B., Nelson J. Production of bacteremia and meningitis in infant rats with group B streptococcal serotypes. Infect Immun. 1980 Mar;27(3):1023–1032. doi: 10.1128/iai.27.3.1023-1032.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fischer G. W., Hunter K. W., Wilson S. R. Type III group B streptococcal strain differences in susceptibility to opsonization with human serum. Pediatr Res. 1981 Dec;15(12):1525–1529. doi: 10.1203/00006450-198112000-00015. [DOI] [PubMed] [Google Scholar]
  8. Hastings M. J., Easmon C. S. Variations in the opsonic requirements of group B streptococcus type III. Br J Exp Pathol. 1981 Oct;62(5):519–525. [PMC free article] [PubMed] [Google Scholar]
  9. Jacks-Weis J., Kim Y., Cleary P. P. Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J Immunol. 1982 Apr;128(4):1897–1902. [PubMed] [Google Scholar]
  10. Johnson D. R., Ferrieri P. Group B streptococcal Ibc protein antigen: distribution of two determinants in wild-type strains of common serotypes. J Clin Microbiol. 1984 Apr;19(4):506–510. doi: 10.1128/jcm.19.4.506-510.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kasper D. L., Baker C. J., Galdes B., Katzenellenbogen E., Jennings H. J. Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. J Clin Invest. 1983 Jul;72(1):260–269. doi: 10.1172/JCI110965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kim Y., Miller K., Michael A. F. Breakdown products of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med. 1977 Apr;89(4):845–850. [PubMed] [Google Scholar]
  13. Klegerman M. E., Boyer K. M., Papierniak C. K., Levine L., Gotoff S. P. Type-specific capsular antigen is associated with virulence in late-onset group B Streptococcal type III disease. Infect Immun. 1984 Apr;44(1):124–129. doi: 10.1128/iai.44.1.124-129.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975 Jul 1;142(1):165–179. doi: 10.1084/jem.142.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Levy N. J., Kasper D. L. Antibody-independent and -dependent opsonization of group B Streptococcus requires the first component of complement C1. Infect Immun. 1985 Jul;49(1):19–24. doi: 10.1128/iai.49.1.19-24.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Levy N. J., Nicholson-Weller A., Baker C. J., Kasper D. L. Potentiation of virulence by group B streptococcal polysaccharides. J Infect Dis. 1984 Jun;149(6):851–860. doi: 10.1093/infdis/149.6.851. [DOI] [PubMed] [Google Scholar]
  17. Lindén V. Mouse-protective effect of rabbit anti-R-protein antibodies against group B streptococci type II carrying R-protein. Lack of effect on type III carrying R-protein. Acta Pathol Microbiol Immunol Scand B. 1983 Apr;91(2):145–151. doi: 10.1111/j.1699-0463.1983.tb00024.x. [DOI] [PubMed] [Google Scholar]
  18. Nealon T. J., Mattingly S. J. Association of elevated levels of cellular lipoteichoic acids of group B streptococci with human neonatal disease. Infect Immun. 1983 Mar;39(3):1243–1251. doi: 10.1128/iai.39.3.1243-1251.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nelson B., Ruddy S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J Immunol. 1979 May;122(5):1994–1999. [PubMed] [Google Scholar]
  20. Payne N. R., Ferrieri P. The relation of the Ibc protein antigen to the opsonization differences between strains of type II group B streptococci. J Infect Dis. 1985 Apr;151(4):672–681. doi: 10.1093/infdis/151.4.672. [DOI] [PubMed] [Google Scholar]
  21. Russell-Jones G. J., Gotschlich E. C., Blake M. S. A surface receptor specific for human IgA on group B streptococci possessing the Ibc protein antigen. J Exp Med. 1984 Nov 1;160(5):1467–1475. doi: 10.1084/jem.160.5.1467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Santos J. I., Shigeoka A. O., Hill H. R. Strain differences in virulence of group B streptococci. Pediatr Res. 1982 May;16(5):347–350. doi: 10.1203/00006450-198205000-00005. [DOI] [PubMed] [Google Scholar]
  23. Shigeoka A. O., Hall R. T., Hemming V. G., Allred C. D., Hill H. R. Role of antibody and complement in opsonization of group B streptococci. Infect Immun. 1978 Jul;21(1):34–40. doi: 10.1128/iai.21.1.34-40.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shigeoka A. O., Jensen C. L., Pincus S. H., Hill H. R. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci. J Infect Dis. 1984 Jul;150(1):63–70. doi: 10.1093/infdis/150.1.63. [DOI] [PubMed] [Google Scholar]
  25. Shigeoka A. O., Rote N. S., Santos J. I., Hill H. R. Assessment of the virulence factors of group B streptococci: correlation with sialic acid content. J Infect Dis. 1983 May;147(5):857–863. doi: 10.1093/infdis/147.5.857. [DOI] [PubMed] [Google Scholar]
  26. Wagner M., Wagner B. Immunoelectron microscopical demonstration of the cell wall and capsular antigens of GBS. Antibiot Chemother (1971) 1985;35:119–127. doi: 10.1159/000410367. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES